Skip to main content
SpringerLink
Log in

Menopausal Hormonal Therapy and Breast Cancer

  • Published:
Advances in Gerontology Aims and scope Submit manuscript

Abstract

The most common treatment for menopausal syndrome is menopausal hormone therapy (MHT), however, the safety of MHT, due to the risk of developing and recurrent breast cancer (BC), is still a matter of debate. The review presents the results of randomized cohort studies of this issue. It has been shown that MHT increases the risk of developing breast cancer and disease recurrence after treatment. The risk of breast cancer developing in women receiving MHT depends on body mass index (BMI), duration of hormone use, and dose of drugs, and is greater in thin women compared with women with increased BMI, and also greater in estrogen–progestin combined MHT users compared with estrogen-only users. It was found that hormone-dependent forms of cancer developed more often in women using MHT, but by the time of diagnosis, the disease was found in more advanced stages and metastases in lymph nodes were found more often when compared with patients who did not use MHT. Risk of breast cancer recurrence is less with low doses of vaginal estrogen. An alternative option for the relief of menopausal disorders in breast cancer patients during and after treatment is using of pineal gland hormone melatonin, since, along with its anti-aging properties, it is able to suppress cancer at the stages of initiation, progression, and metastasis and has the ability to reduce the toxic effects of anticancer drugs simultaneously increasing their effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Anisimov, V.N., Melatonin and its place in modern medicine, Russ. Med. Zh., 2006, no. 4, pp. 269–274. http://www.rmj.ru/articles/obshchie.

  2. Anisimov, V.N. and Vinogradova, I.A., Starenie zhenskoi reproduktivnoi sistemy i melatonin (Aging of Female Reproductive System of Melatonin), St. Petersburg: Sistema, 2008.

  3. Bershtein, L.M., Gormonal’nyi kantserogenez (Hormonal Carcinogenesis), St. Petersburg: Nauka, 2000.

  4. Bryukhina, E. and Usol’tseva, E., Melatonin is the key to adaptation of the female body in climacteric syndrome, Vrach, 2016, no. 4, pp. 68–71.

  5. Gershanovich, M.L., Garin, A.M., Baltinya, D., et al., Results of a third clinical study of tamoxifen and toremifen in two different doses for treatment of wild-spread breast cancer in women with postmenopause, Vopr. Onkol., 1997, vol. 43, no. 6, pp. 587–595.

    CAS  PubMed  Google Scholar 

  6. Zlokachestvennye novoobrazovaniya v Rossii v 2018 godu (zabolevaemost’ i smertnost’) (Cases of Malignant Neoplasms in Russia in 2018: Morbidity and Mortality), Kaprin, A.D., Starinskii, and Petrova, G.V., Eds., Moscow: Mosk. Nauchno-Issled. Onkol. Inst. im. P.A. Gertsena, 2019.

  7. WHO Scientific Group on Research on the Menopause: World Health Organisation Technical Report Series No. 670, Geneva: World Health Org., 1989.

  8. Menopazuza i klimaktericheskoe sostoyanie u zhenshchiny: Klinicheskie rekomendatsii (Menopause and Climacteric State in a Woman: Clinical Guide), Moscow, 2016.

  9. Prilepskaya, V.N., Menopause syndrome: innovations in menopausal therapy, Russ. Med. Zh., Mat’ Ditya, 2017, no. 2, pp. 105–108.

  10. Serov, V.N., Prilepskaya, V.N., and Ovsyannikova, T.N., Rukovodstvo po ginekologicheskoi endokrinologii (Guide on Gynecological Endocrinology), Moscow: Medpress-Inform, 2008.

  11. Smetnik, V.P. and Konovalova, V.N., Hormone replacement therapy and breast cancer risk in postmenopausal women: an analysis of some epidemiological studies, Ross. Onkol. Zh., 2011, vol. 2, pp. 53–56.

    Google Scholar 

  12. Sukhikh, G.T., Smetnik, V.P., and Andreeva, E.N., Menopausal hormone therapy and health maintenance of women: clinical guide, Probl. Reprod., 2016, pp. 8–9.

  13. Semiglazov, V.F., Paltuev, R.M., Semiglazov, V.V., et al., General St. Gallen-2015 guidelines for the treatment of early breast cancer (adapted by the experts of the Russian Society of Breast Oncologists), Opukholi Zhen. Reprod. Sist., 2015, vol. 11, no. 3, pp. 43–60.

    Google Scholar 

  14. Axlund, S.D. and Sartorius, C.A., Progesterone regulation of stem and progenitor cells in normal and malignant breast, Mol. Cell. Endocrinol., 2012, vol. 24, no. 357, pp. 71–79.

    Google Scholar 

  15. Batur, P., Blixen, C.E., Moore, H.C., et al., Menopausal hormone therapy (HT) in patients with breast cancer, Maturitas, 2006, vol. 20, no. 53, pp. 123–132.

    Google Scholar 

  16. Bhattacharya, S., Patel, K.K., Dehari, D., et al., Melatonin and its ubiquitous anticancer effects, Mol. Cell. Biochem., 2019, vol. 462, nos. 1–2, pp. 133–155.

  17. Beral, V., et al., Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet, 2003, vol. 362, no. 9382, pp. 419–427.

    CAS  PubMed  Google Scholar 

  18. Beral, V., Reeves, G., Bull, D., and Green, J., For the Million Women Study Collaborators Breast cancer risk in relation to the interval between menopause and starting hormone therapy, J. Natl. Cancer Inst., 2011, vol. 103, pp. 296–305.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Bray, F., Ferlay, J., Soerjomataram, I., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA–Cancer J. Clin., 2018, vol. 68, no. 6, pp. 394–424.

    PubMed  Google Scholar 

  20. Chen, W.Y., Manson, J.E., Hankinson, S.E., et al., Unopposed estrogen therapy and the risk of invasive breast cancer, Arch. Int. Med., 2006, vol. 166, no. 9, pp. 1027–1032.

    CAS  Google Scholar 

  21. Chlebowski, R.T., Manson, J.E., Anderson, G.L., et al., Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study, J. Nat. Cancer Inst., 2013, vol. 105, no. 8, pp. 526–535. https://doi.org/10.1093/jnci/djt043

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Cobin, R.H., Goodman, N.F., et al., American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update, Endocrinol. Pract., 2017, vol. 23, no. 7, pp. 869–880.

    Google Scholar 

  23. Col, N.F., Kim, J.A., and Chlebowski, R.T., Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence, Breast Cancer Res., 2005, vol. 7, no. 4, pp. 535–540.

    Google Scholar 

  24. Collaborative Group on Hormonal Factors in Breast Cancer, Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence, Lancet, 2019, vol. 394, pp. 1159–1168.

    PubMed Central  Google Scholar 

  25. Curigliano, G., Burstein, H.J., Winer, E.P., et al., De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017, Ann. Oncol., 2017, vol. 28, no. 8, pp. 1700–1712.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. DiSaia, P.J., Brewster, W.R., Ziogas, A., and Anton-Culver, H., Breast cancer survival and hormone replacement therapy: a cohort analysis, Am. J. Clin. Oncol., 2000, vol. 23, no. 6, pp. 541–545.

    CAS  PubMed  Google Scholar 

  27. Emons, G., Mustea, A., and Tempfer, C., Tamoxifen and endometrial cancer: a Janus-headed drug, Cancers (Basel), 2020, vol. 12, no. 9, p. 2535.

    CAS  PubMed Central  Google Scholar 

  28. Fahlén, M., Fornander, T., and Johansson, H., Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomized trial, Eur. J. Cancer, 2013, vol. 49, no. 1, pp. 52–59.

  29. Fournier, A., Berrino, F., Riboli, E., et al., Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int. J. Cancer, 2005, vol. 114, no. 3, pp. 448–454.

    CAS  PubMed  Google Scholar 

  30. Fournier, A., Mesrine, S., Dossus, L., et al., Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort, Breast Cancer Res. Treat., 2014, vol. 145, pp. 535–543.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Godfrey, H.M., Armour, M., and McBride, K.A., Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: a systematic review and meta-analysis, Breast, 2019, vol. 47, pp. 43–55.

    Google Scholar 

  32. Grady, D., Rubin, S.M., Petitti, D.B., et al., Hormone therapy to prevent disease and prolong life in postmenopausal women, Ann. Int. Med., 1992, vol. 117, no. 12, pp. 1016–1037.

    CAS  PubMed  Google Scholar 

  33. Greiser, C.M., Greiser, E.M., and Doren, M., Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials, Hum. Reprod. Update, 2005, vol. 11, pp. 561–573.

    CAS  PubMed  Google Scholar 

  34. Grodstein, F., Manson, J.E., Colditz, G.A., et al., A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease, Ann. Int. Med., 2000, vol. 133, pp. 933–941.

    CAS  PubMed  Google Scholar 

  35. Grosse, Y., Baan, R., Straif, K., et al., A review of human carcinogens—Part A: pharmaceuticals, Lancet Oncol., 2009, vol. 10, pp. 13–14.

    PubMed  Google Scholar 

  36. Holmberg, L., Anderson, H., et al., HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomized comparison: trial stopped, Lancet, 2004, vol. 363, no. 9407, pp. 453–455.

    CAS  PubMed  Google Scholar 

  37. Hong, J., Huang, J., Shen, L., et al., A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis, BMC Cancer, 2020, vol. 20, no. 1, p. 663.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Hunter, M.M., Huang, A.J., and Wallhagen, M.I., “I’m going to stay young”: belief in anti-aging efficacy of menopausal hormone therapy drives prolonged use despite medical risks, PLoS One, 2020, vol. 15, no. 5, p. e0233703.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy, IARC Monogr. Eval. Carcinog. Risks Hum., vol. 91, Lyon: Int. Agency Res. Cancer, 2008.

  40. Kumle, M., Declining breast cancer incidence and decreased HT use, Lancet, 2008, vol. 372, no. 9639, pp. 608–610.

    PubMed  Google Scholar 

  41. La Croix, A.Z., Chlebowski, R.T., Manson, J.E., et al., Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial, J.A.M.A., 2011, vol. 305, no. 13, pp. 1305–1314.

    CAS  Google Scholar 

  42. Le Romancer, M., Poulard, C., Cohen, P., et al., Cracking the estrogen receptor’s posttranslational code in breast tumors, Endocrinol. Rev., 2011, vol. 32, no. 5, pp. 597–622.

    CAS  Google Scholar 

  43. Li, F., Dou, J., Wei, L., et al., The selective estrogen receptor modulators in breast cancer prevention, Cancer Chemother. Pharmacol., 2016, vol. 77, no. 5, pp. 895–903.

    CAS  PubMed  Google Scholar 

  44. Lupo, M., Dains, J.E., and Madsen, L.T., Hormone replacement therapy: an increased risk of recurrence and mortality for breast cancer patients?, J. Adv. Pract. Oncol., 2015, vol. 6, no. 4, pp. 322–330.

    PubMed  PubMed Central  Google Scholar 

  45. Marsden, J., Whitehead, M., A’Hern, R., et al., Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?, Fertil. Steril., 2000, vol. 73, no. 2, pp. 292–299.

    CAS  PubMed  Google Scholar 

  46. UK Public Assessment Report: Hormone-Replacement Therapy: Safety Update, London: Med. Healthcare Prod. Regul. Agency, 2007.

  47. Meurer, L.N. and Lená, S., Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis, J. Fam. Pract., 2002, vol. 51, no. 12, pp. 1056–1062.

    PubMed  Google Scholar 

  48. Mudhune, G.H., Armour, M., and McBride, K.A., Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: a systematic review and meta-analysis, Breast, 2019, vol. 47, pp. 43–55.

    PubMed  Google Scholar 

  49. Murphy, L.C. and Leygue, E., The role of estrogen receptor-β in breast cancer, Semin. Reprod. Med., 2012, vol. 30, no. 1, pp. 5–13.

    CAS  PubMed  Google Scholar 

  50. Nelson, H.D., Smith, M.E., Griffin, J., and Fu, R., Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force, Ann. Int. Med., 2013, vol. 158, no. 8, pp. 604–614.

    PubMed  Google Scholar 

  51. North American Menopause Society, The 2012 hormone therapy position statement of: the North American Menopause Society, Menopause, 2012, vol. 19, no. 3, pp. 257–271.

    Google Scholar 

  52. Figueiredo, J.C., Haile, R.W., Bernstein, L., et al., Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study, Breast Cancer Res. Treat., 2010, vol. 120, no. 1, pp. 175–183.

    CAS  PubMed  Google Scholar 

  53. Osborne, C.K., Tamoxifen in the treatment of breast cancer, N. Engl. J. Med., 1998, vol. 339, no. 22, pp. 1609–1618.

    CAS  PubMed  Google Scholar 

  54. Pinkerton, J.V. and Thomas, S., Use of SERMs for treatment in postmenopausal women, J. Steroid Biochem. Mol. Biol., 2014, vol. 142, pp. 142–154.

    CAS  PubMed  Google Scholar 

  55. Prentice, R.L., Chlebowski, R.T., Stefanick, M.L., et al., Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study, Am. J. Epidemiol., 2008, vol. 167, no. 12, pp. 1407–1415.

    PubMed  Google Scholar 

  56. Ravdin, P.M., Cronin, K.A., Howlader, N., et al., The decrease in breast-cancer incidence in 2003 in the United States, N. Engl. J. Med., 2007, vol. 356, no. 16, pp. 1670–1674.

    CAS  PubMed  Google Scholar 

  57. Reiter, R.J., Rosales-Corral, S.A., Tan, D.X., et al., Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis, Int. J. Mol. Sci., 2017, vol. 18, no. 4, p. 843.

    PubMed Central  Google Scholar 

  58. Román, M., Sakshaug, S., Graff-Iversen, S., et al., Postmenopausal hormone therapy and the risk of breast cancer in Norway, Int. J. Cancer, 2016, vol. 138, no. 3, pp. 584–593.

  59. Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial, J.A.M.A., 2002, vol. 288, no. 3, pp. 321–333.

    CAS  PubMed  Google Scholar 

  60. Samavat, H. and Kurzer, M.S., Estrogen metabolism and breast cancer, Cancer Lett., 2015, vol. 356, pp. 231–243.

    CAS  PubMed  Google Scholar 

  61. Santen, R.J., Allred, D.C., Ardoin, S.P., et al., Postmenopausal hormone therapy: an endocrine society scientific statement, Clin. Endocrinol. Metab., 2010, vol. 95, no. 7, pp. s1–s66.

    CAS  Google Scholar 

  62. Schoenaker, D.A., Jackson, C.A., Rowlands, J.V., and Mishra, G.D., Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents, Int. J. Epidemiol., 2014, vol. 43, pp. 1542–1562.

    PubMed  PubMed Central  Google Scholar 

  63. Stefanick, M.L., Anderson, G.L., Margolis, K.L., et al., Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy, J.A.M.A., 2006, vol. 295, no. 14, pp. 1647–1657.

    CAS  PubMed  Google Scholar 

  64. Treeck, O., Lattrich, C., Springwald, A., and Ortmann, O., Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells, Breast Cancer Res. Treat., 2010, vol. 120, no. 3, pp. 557–565.

    CAS  PubMed  Google Scholar 

  65. Verheul, H.A., Coelingh-Bennink, H.J., Kenemans, P., et al., Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies, Maturitas, 2000, vol. 36, pp. 1–17.

    CAS  PubMed  Google Scholar 

  66. van Hellemond, I.E.G., Geurts, S.M.E., and Tjan-Heijnen, V.C.G., Current status of extended adjuvant endocrine therapy in early stage breast cancer, Curr. Treat. Options Oncol., 2018, vol. 19, no. 5, p. 26.

    PubMed  PubMed Central  Google Scholar 

  67. von Schoultz, E., Rutqvist, L.E., et al., Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial, J. Nat. Cancer Inst., 2005, vol. 97, no. 7, pp. 533–535.

    CAS  PubMed  Google Scholar 

  68. Wang, K., Li, F., Chen, L., et al., Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies, Oncotarget, 2017, vol. 8, no. 46, pp. 81109–81124.

    PubMed  PubMed Central  Google Scholar 

  69. Warner, M. and Gustafsson J.-Å., The role of estrogen receptor β(ERβ) in malignant diseases—a new potential target for antiproliferative drugs in prevention and treatment of cancer, Biochem. Biophys. Res. Commun., 2010, vol. 396, no. 1, pp. 63–66.

    CAS  PubMed  Google Scholar 

  70. Yager, J.D. and Davidson, N.E., Estrogen carcinogenesis in breast cancer, N. Engl. J. Med., 2006, vol. 354, no. 3, pp. 270–282.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Petrov National Medical Research Center of Oncology, 197758, St. Petersburg, Russia

    E. V. Bakhidze, I. V. Berlev, V. N. Anisimov & A. M. Belyaev

  2. Mechnikov North-Western State Medical University, 191015, St. Petersburg, Russia

    E. V. Bakhidze, A. V. Belyaeva, I. V. Berlev & A. M. Belyaev

Authors
  1. E. V. Bakhidze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. V. Belyaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. V. Berlev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. N. Anisimov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. M. Belyaev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. V. Bakhidze.

Ethics declarations

The authors declare they have no conflicts of interest. This article does not contain any studies involving animals or human participants performed by any of the authors.

Additional information

Translated by L. Solovyova

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bakhidze, E.V., Belyaeva, A.V., Berlev, I.V. et al. Menopausal Hormonal Therapy and Breast Cancer. Adv Gerontol 11, 382–390 (2021). https://doi.org/10.1134/S2079057021040020

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S2079057021040020

Keywords:

Search

Navigation